Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 2
---
ERO.” On February 5, 2025, the last quoted sale price for the shares of our Common Stock as reported on the Nasdaq was $1.96 per share.

Our existing public
warrants (the “Public Warrants”) are listed on Nasdaq under the symbol “CEROW,” and the last reported sale price
of the Public Warrants on Nasdaq on February 5, 2025 was $0.0149 per Public Warrant. The Offered Common Warrants do not have the same
terms and conditions as our Public Warrants. The actual number of securities, and the combined offering price per share of Common Stock
and the accompanying Offered Common Warrants, and the exercise price for the accompanying Offered Common Warrants will be as determined
between us and investors at the time of pricing, and may be at a discount to the current market price of our Common Stock and the Public
Warrants. Therefore, the recent market prices used throughout this prospectus may not be indicative of the actual public offering price
of the shares of Common Stock and accompanying Offered Common Warrants. Currently, there is no public market for the Offered Common Warrants.

We are an “emerging growth company” under applicable federal securities laws and are subject to reduced public company reporting requirements.

We have engaged A.G.P./Alliance
Global Partners (“A.G.P” or the “placement agent”) to act as our exclusive placement agent in connection with
this offering. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by
this prospectus. The placement agent is not purchasing or selling any of the securities we are offering and the placement agent is not
required to arrange the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay the placement agent
the placement agent fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. Since
we will deliver the securities to be issued in this offering upon our receipt of investor funds, there is no arrangement for funds to
be received in escrow, trust or similar arrangement.

There is no minimum offering
requirement as a condition of closing of this offering. Because there is no minimum offering amount required as a condition to closing
this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received
by us, and investors in this offering will not receive a